Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants

Jack Ansell, Bryan E. Laulicht, Sasha H. Bakhru, Allison Burnett, Xuan Jiang, Lirong Chen, Christopher Baker, Stephen Villano, Solomon Steiner

Blood (2021) 137 (1): 115–125.

https://doi.org/10.1182/blood.2020007116

Published: 2021

Includes: Supplemental data

Journal Articles

Reversal of Anticoagulation By Ciraparantag: Time to Onset and Duration of Effect

Jack Ansell, MD, Bryan Laulicht, PhD, Sasha Bakhru, PhD, Xiaohui Luo, PhD, Stephen Villano, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-140524

Published: 2020

Journal Articles

Design of a Randomized, Controlled Study to Evaluate Reversal of Anticoagulation of Ciraparantag in Healthy Adults: Whole Blood Clotting Time Assessed By Automated and Manual Methods

Stephen Villano, MD, Sasha Bakhru, PhD, Xiaohui Luo, PhD, Daniel Freedman, PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142798

Published: 2020

Journal Articles

Pharmacokinetics of Oral Maribavir, a Novel Anti-Cytomegalovirus Agent, in Subjects with Renal Impairment.

Suzanne Swan, William Smith, Thomas Marbury, Mary Schumacher, Carolyn Dougherty, Bruce Mico, Stephen Villano

Blood (2006) 108 (11): 2863.

https://doi.org/10.1182/blood.V108.11.2863.2863

Published: 2006

Journal Articles

Prophylaxis Against Cytomegalovirus Infections with Oral Maribavir in Allogeneic Stem Cell Transplant Recipients: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.

Drew Winston, Jo-Anne van Burik, Vinod Pullarkat, Genovefa Papanicolaou, Ravi Vij, Estil Vance, George Alangaden, Roy Chemaly, Finn Petersen, Nelson Chao, Jared Klein, Kellie Sprague, Carolyn Dougherty, Stephen Villano, Michael Boeckh

Blood (2006) 108 (11): 593.

https://doi.org/10.1182/blood.V108.11.593.593

Published: 2006

NARROW

Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants

Reversal of Anticoagulation By Ciraparantag: Time to Onset and Duration of Effect

Design of a Randomized, Controlled Study to Evaluate Reversal of Anticoagulation of Ciraparantag in Healthy Adults: Whole Blood Clotting Time Assessed By Automated and Manual Methods

Pharmacokinetics of Oral Maribavir, a Novel Anti-Cytomegalovirus Agent, in Subjects with Renal Impairment.

Prophylaxis Against Cytomegalovirus Infections with Oral Maribavir in Allogeneic Stem Cell Transplant Recipients: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.

Email alerts

ASH Publications

American Society of Hematology

Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants

Reversal of Anticoagulation By Ciraparantag: Time to Onset and Duration of Effect

Design of a Randomized, Controlled Study to Evaluate Reversal of Anticoagulation of Ciraparantag in Healthy Adults: Whole Blood Clotting Time Assessed By Automated and Manual Methods

Pharmacokinetics of Oral Maribavir, a Novel Anti-Cytomegalovirus Agent, in Subjects with Renal Impairment.

Prophylaxis Against Cytomegalovirus Infections with Oral Maribavir in Allogeneic Stem Cell Transplant Recipients: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only